LEXINGTON, Mass.--(BUSINESS WIRE)--NitroMed, Inc. (NASDAQ: NTMD), an emerging pharmaceutical company and the maker of BiDil® (the fixed dose combination of isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine approved in the United States for the treatment of heart failure in self-identified black patients, said today that five abstracts will be presented at the 11th Annual Scientific Meeting of the Heart Failure Society of America taking place September 16-19, 2007 in Washington, DC.
